retatrutide type 2 diabetes trial 2024 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide Phase 2: Type 2

It combines the actions of two different hormones to target multiple pathways involved in glucose and weight regulation

In 2023, a record 10,660 liver transplants were performed in the United States alone, with MASH accounting for 27% of these procedures, making it the second leading indication for liver transplantation

Slide from Peter Rossings presentation- Current treatment strategies, unmet medical need, FLOW rationale, during FLOW session, 61st European Renal Association Congress The 4th pillar of DKD came as from a splash from the past

Results vary, but many patients lose 1020% of their body weight with medical supervision and lifestyle support

Interestingly, the same group could demonstrate that treatment with Liraglutide at 10nM enhanced the migration capacity of hBMSC, suggesting context-specific effects of the drug beyond its influence on proliferation [21]

Long-term effects unknown : While the clinical trials look good, the long-term safety and efficacy of tirzepatide, especially for weight loss, is still being studied